Caricamento...
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ(25‐35)‐induced anxiety and cognitive deficits in a mouse model
AIMS: Recently, histone deacetylase (HDAC) inhibitors are considered a possible therapeutic strategy in Alzheimer's disease (AD). However, HDACi treatments exhibit diverse functions with unfavorable effects in AD. Thus, the development of selective HDACi without side effects is urgently needed....
Salvato in:
| Pubblicato in: | CNS Neurosci Ther |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488906/ https://ncbi.nlm.nih.gov/pubmed/29978554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13029 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|